Kidswell Bio Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Public

  • Employees
  • 37

Employees

  • Stock Symbol
  • 4584

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $1.80
  • (As of Monday Closing)

Kidswell Bio General Information

Description

Kidswell Bio Corp is a biopharmaceutical company engaged in the discovery and development of drugs.

Contact Information

Website
www.kidswellbio.com
Formerly Known As
Gene Techno Science Co., Ltd., Gene Techno, Gene Techno Science Co, Gene Techno Sciences, Gene Techno Science
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 3rd Floor, Kanayama Building
  • 1-2-12, Shinkawa
  • Tokyo, Chuo-ku
  • Japan
+81
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
TKS
Corporate Office
  • 3rd Floor, Kanayama Building
  • 1-2-12, Shinkawa
  • Tokyo, Chuo-ku
  • Japan
+81

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kidswell Bio Stock Performance

As of 14-Jul-2025, Kidswell Bio’s stock price is $1.80. Its current market cap is $85.6M with 47.6M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.80 $1.72 $0.60 - $2.88 $85.6M 47.6M 5.47M

Kidswell Bio Financials Summary

As of 31-Mar-2025, Kidswell Bio has a trailing 12-month revenue of $33.3M.

In Thousands,
USD 		TTM 31-Mar-2025 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024 FY 2023 31-Mar-2023
EV 33,494 33,494 38,934 65,975
Revenue 33,328 33,328 16,826 20,507
EBITDA 757 757 (9,557) (4,583)
Net Income (139) (139) (9,842) (4,856)
Total Assets 46,835 46,835 33,601 29,230
Total Debt 12,282 12,282 17,014 14,635
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kidswell Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kidswell Bio‘s full profile, request access.

Request a free trial

Kidswell Bio Patents

  • 136

    Total Documents Applications and Grants

  • Total Patents Families

  • 66

    Granted

  • 7

    Pending

  • Expiring in next 12 mo

Kidswell Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023357562-A1 Novel dental pulp stem cell population Pending 03-Oct-2022
JP-WO2019216438-A1 Periodontal disease therapeutic agent containing culture supernatant of mesenchymal cells Pending 11-May-2018
CA-3075867-A1 Anti-ramp2 antibody Inactive 13-Sep-2017
JP-2022169737-A Anti-ramp2 antibody Pending 13-Sep-2017
JP-7202011-B2 Anti-ramp2 antibody Active 13-Sep-2017
To view Kidswell Bio’s complete patent history, request access »

Kidswell Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kidswell Bio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Kidswell Bio‘s full profile, request access.

Request a free trial

Kidswell Bio Investments & Acquisitions (4)

Kidswell Bio’s most recent deal was a Later Stage VC with Heartseed for . The deal was made on 11-Mar-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Heartseed 11-Mar-2020 Later Stage VC Drug Discovery
Advanced Cell Technology and Engineering 17-Jan-2019 Merger/Acquisition Other Healthcare Services
Advanced Cell Technology and Engineering 30-Mar-2018 Later Stage VC Other Healthcare Services
OrthoReBirth 27-Nov-2014 Seed Round Other Devices and Supplies
To view Kidswell Bio’s complete investments and acquisitions history, request access »

Kidswell Bio ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Kidswell Bio’s complete esg history, request access »

Kidswell Bio Exits (3)

Kidswell Bio’s most recent exit was on 11-Mar-2020 from Heartseed. The exit was categorized as with 8 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Heartseed 11-Mar-2020 Completed
  • 8 buyers
Advanced Cell Technology and Engineering 17-Jan-2019 Completed
Advanced Cell Technology and Engineering 30-Mar-2018 Later Stage VC Completed
  • 2 buyers
To view Kidswell Bio’s complete exits history, request access »

Kidswell Bio FAQs

  • When was Kidswell Bio founded?

    Kidswell Bio was founded in 2001.

  • Where is Kidswell Bio headquartered?

    Kidswell Bio is headquartered in Tokyo, Japan.

  • What is the size of Kidswell Bio?

    Kidswell Bio has 37 total employees.

  • What industry is Kidswell Bio in?

    Kidswell Bio’s primary industry is Biotechnology.

  • Is Kidswell Bio a private or public company?

    Kidswell Bio is a Public company.

  • What is Kidswell Bio’s stock symbol?

    The ticker symbol for Kidswell Bio is 4584.

  • What is the current stock price of Kidswell Bio?

    As of 14-Jul-2025 the stock price of Kidswell Bio is $1.80.

  • What is the current market cap of Kidswell Bio?

    The current market capitalization of Kidswell Bio is $85.6M.

  • What is Kidswell Bio’s current revenue?

    The trailing twelve month revenue for Kidswell Bio is $33.3M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »